BIOAApproval•prnewswire•
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease
Sentiment:Positive (80)
Summary
(NASDAQ:BIOA) STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab subcutaneous injection for maintenance dosing....
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 29, 2025 by prnewswire